GleamWall
中文EN

UPB Upstream Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2022626 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.5%
TTM net income YoY-34.1%
TTM EPS YoY-128.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-6,116.0%
Net margin-5,712.3%
FCF margin—
EBITDA margin-6,108.9%

Returns

ROE-53.5%
ROA-51.5%
ROIC (approx.)-56.3%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets4.9%
Debt / equity0.00x
Current ratio20.45x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$395,000$773,000$1.03M$668,000$683,000$937,000$566,000$613,000
R&D expense$36.61M$36.09M$36.56M$40.17M$32.98M$37.87M$25.80M$21.77M
SG&A expense$7.17M$7.05M$8.08M$6.67M$5.54M$7.42M$6.78M$5.16M
Operating income-$43.38M-$42.37M-$43.62M-$46.17M-$37.83M-$44.35M-$32.01M-$26.32M
Income tax$0$0$0$0$0$0$0$0
Net income-$41.19M-$39.70M-$40.59M-$42.46M-$33.75M-$39.97M-$27.27M-$21.24M
EBITDA-$43.33M-$42.32M-$43.57M-$46.11M-$37.79M-$44.30M-$31.97M-$26.27M
EPS (basic)-0.75-0.73-0.75—-0.63-0.74-0.51—
EPS (diluted)-0.75-0.73-0.75—-0.63-0.74-0.51—
Weighted avg. shares (diluted)54.78M54.57M54.33M—53.93M53.77M53.62M—
Balance sheet
Cash & equivalents$47.42M$79.40M$96.72M$101.58M$72.16M$45.46M$71.31M$325.89M
Short-term investments$159.95M$181.91M$197.85M$239.93M$300.26M$348.12M$360.07M$144.56M
Receivables$395,000$772,000$1.03M$668,000$683,000$937,000$566,000$613,000
Current assets$244.63M$279.60M$316.28M$351.80M$389.02M$418.27M$453.79M$479.16M
PP&E, net$411,000$460,000$510,000$559,000$616,000$544,000$539,000$582,000
Goodwill———————$0
Total assets$245.99M$281.17M$318.05M$353.77M$391.19M$420.52M$456.17M$481.72M
Current liabilities$11.96M$9.99M$13.67M$13.45M$11.91M$10.93M$9.57M$10.74M
Total liabilities$12.02M$10.21M$14.06M$14.00M$12.61M$11.78M$10.56M$11.87M
Shareholders' equity$233.97M$270.96M$304.00M$339.77M$378.58M$408.74M$445.61M$469.85M
Shares outstanding54.81M54.77M54.42M54.24M54.00M53.80M53.64M53.60M
Cash flow statement
Operating cash flow-$54.23M-$35.62M-$47.85M-$30.63M-$22.24M-$39.24M-$41.16M-$19.61M
Capital expenditure$0——$54,000$64,000——$185,000
Free cash flow-$54.23M——-$30.68M-$22.30M——-$19.80M
Investing cash flow$22.18M$15.76M$42.40M$58.94M$48.19M$12.77M-$213.38M$41.91M
Financing cash flow$69,000$2.53M$598,000$1.10M$760,000$612,000-$34,000$270.65M
Depreciation & amortization$49,000$50,000$49,000$57,000$46,000$42,000$43,000$49,000
Stock-based compensation$4.34M$4.35M$4.65M$2.51M$2.59M$2.60M$2.63M$2.09M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.